Opportunities and Key Players in Medical Nutrition
NEW YORK, Aug. 8, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Opportunities and Key Players in Medical Nutrition
http://www.reportlinker.com/p0591014/Opportunities-and-Key-Players-in-Medical-Nutrition.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
Introduction
A small number of products for specific diseases have been introduced over the years, but companies have only recently started to focus on the specific nutritional requirements of patients with different diseases in depth. This report examines the potential of this burgeoning market by identifying areas of unmet need and the companies looking to cater to this demand with new product development.
Features and benefits
* Explore the medical nutrition market as it stands and assess its future potential.
* Identify factors affecting the future growth of the market
* Identify the key therapeutic areas in which there are established products or that represent areas of active interest for the future.
* Understand how medical nutrition products are developed, regulated and reimbursed.
* Identify the key market players and their interest in the future growth of the medical nutrition sector.
Highlights
The growing, aging population and the fact that healthcare systems across the globe are under financial pressure are driving interest in this emerging area. Research is, for example, investigating the possibility that integrating nutrition in therapeutic schedules for cancer might improve treatment outcomes.
The potential rewards for introducing new products for use by patients with specific diseases are significant, as deomnstrated by the billion dollar pharmaceutical markets they represent. However, considerable challenges to this growing market exist - as yet, no market definition exists and regulatory requirements remain unclear.
Clinical trials for medical nutrition products are necessary to demonstrate the efficacy and tolerability of new products and to provide support for any labeling claims. They usually follow standards set in the pharmaceutical arena, including elements such as randomization, the use of controls and double blinding and must stand up to peer review.
Your key questions answered
* What are medical nutrition products?
* In which therapeutic areas is there a market for medical foods?
* Which companies are currently in the medical nutrition market and which groups are driving the sector forward?
* How are they going to achieve the development, approval and launch of medical foods in therapeutic areas not conventionally treated with food?
* What are the key factors affecting the development of the medical nutrition market?
Executive Summary
Overview and epidemiology of women's health
Global market analysis
Pipeline analysis
Competitive landscape
About the author
Disclaimer
Overview and epidemiology of women's health
Summary
Introduction
Osteoporosis
Overview
Diagnosis treatment and management
Epidemiology
Forecast epidemiology
Hormonal contraception
Overview
Diagnosis treatment and management
Epidemiology
Forecast epidemiology
Hormone replacement therapies
Overview
Diagnosis, treatment and management
Infertility treatment
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Global market analysis
Summary
Market analysis by geography
Market analysis by therapy area
Hormonal contraceptives
Osteoporosis treatment
Hormone replacement therapy (HRT)
Infertility treatment
Key events in women's health market
Merck Serono sells women's health division to Teva
Gedeon Richter extends women's health franchise with PregLem acquisition
Boehringer Ingelheim discontinued the development of its female desire drug, flibanserin
Eli Lilly's arzoxifene misses secondary endpoint in critical osteoporosis trial
Bayer's Yaz and Yasmin get US label update
Research deal between Bayer and Chinese hospital for women's health
Leading brand dynamics
Actonel (Risedronate) – Warner Chilcott, Sanofi
Evista (raloxifene) – Eli Lilly
Bonviva/Boniva (ibandronic acid) – Roche/GlaxoSmithKline
Premarin (conjugated estrogens) – Pfizer
Fosamax (alendronate) – Merck & Co
Yaz/Yasmin (drospirenone + ethinyl estradiol) – Bayer
Mirena (levonorgestrel) – Bayer
Gonal F (follitropin beta) – Merck KGaA
NuvaRing (ethinyl estradiol + etonogestrel) – Merck & Co.
Global women's health sales forecast
Pipeline analysis
Summary
Introduction
Women's health pipeline
Leading drugs in development
Profiles of key pipeline products
Prolia (denosumab) – Amgen
Viviant/Conbriza (bazedoxifene) – Pfizer
LCS (ultra low-dose levonorgestrel releasing IUD) – Bayer
Aprela (bazedoxifene and conjugated estrogen) – Pfizer
MK-0822 (odanacatib) – Merck
Elonva (corifollitropin alfa) – Merck
Nomac E2 (nomegestrol and estradiol) – Merck & Co.
WC3026/ Generess (norethindrone + ethinyl estradiol) – Warner Chilcott/Watson
Natazia/Qlaira (estradiol valerate and dienogest) – Bayer
SMC021 (synthetic oral salmon calcitonin) – Novartis
FC Patch Low (gestodene and ethinyl estradiol transdermal patch) – Bayer
DR2011 (progesterone vaginal ring) – Teva
EllaOne (ulipristal acetate) – HRA Pharma/Watson
Pipeline forecast of leading drugs in development
Competitive landscape
Summary
Introduction
Sales performance of leading players
Bayer
Marketed product portfolio
Pipeline analysis
Strategic and growth analysis
Merck & Co.
Marketed product portfolio
Pipeline analysis
Strategic and growth analysis
Eli Lilly
Marketed product portfolio
Pipeline analysis
Strategic and growth analysis
Warner Chilcott
Marketed product portfolio
Pipeline analysis
Strategic and growth analysis
Pfizer
Marketed product portfolio
Pipeline analysis
Strategic and growth analysis
Teva
Marketed product portfolio
Pipeline analysis
Strategic and growth analysis
Appendix
Scope
Key women's health diseases covered in this report
Methodology
Epidemiology forecast
Market forecast
Epidemiology forecast
References
Journal articles
Conference proceedings
Important websites
Glossary/abbreviations
To order this report:
Drug and Medication Industry: Opportunities and Key Players in Medical Nutrition
Drug and Medication Business News
Check our Company Profile, SWOT and Revenue Analysis!
CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article